Trial site
Texas Oncology-Austin Midtown
Austin, Texas 78705, United StatesNot linked to an institution yet
- 9running trials
- 15closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 16 trials
- Phase 25 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting8 trials
- Completed8 trials
- Terminated7 trials
- Recruiting1 trial
- Lead sponsor
- NRG Oncology3 trials
- Seagen Inc.3 trials
- Hoffmann-La Roche2 trials
- National Cancer Institute (NCI)2 trials
- Radiation Therapy Oncology Group2 trials
- and 12 more
Running trials
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· Phase 3· Kura Oncology, Inc.· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Erasca, Inc.· Source
Active, not recruiting
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
NCT05608044· Phase 2· Agenus Inc.· Source
Active, not recruiting
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· Phase 3· Epizyme, Inc.· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Active, not recruiting
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086· Phase 2· NRG Oncology· Source
Active, not recruiting
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007· Phase 3· Radiation Therapy Oncology Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
NCT05479812· Phase 1· Werewolf Therapeutics, Inc.· Source
Terminated
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT05169437· Phase 2· Tempus AI· Source
Terminated
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
NCT04999202· Phase 1· Bayer· Source
Completed
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
NCT04191616· Phase 2· Amgen· Source
Terminated
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
NCT04254107· Phase 1· Seagen Inc.· Source
Terminated
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
NCT03893682· Phase 1· Aptose Biosciences Inc.· Source
Terminated
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
NCT03646123· Phase 2· Seagen Inc.· Source
Terminated
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
NCT03582033· Phase 1· Seagen Inc.· Source
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977· Phase 1· Pfizer· Source
Completed
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
NCT03274492· Phase 3· Hoffmann-La Roche· Source
Completed
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03037385· Phase 1/2· Hoffmann-La Roche· Source
Completed
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
NCT02364557· Phase 2/3· NRG Oncology· Source
Completed
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01013649· Phase 3· National Cancer Institute (NCI)· Source
Completed
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
NCT00936390· Phase 3· Radiation Therapy Oncology Group· Source
Completed
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
NCT00217737· Phase 3· National Cancer Institute (NCI)· Source
Report an error